盐酸安罗替尼联合TP化疗方案治疗晚期食管癌患者的效果

Effects of Anlotinib hydrochloride combined with TP chemotherapy regimen in treatment of patients with advanced esophageal cancer

目的:观察盐酸安罗替尼联合TP化疗方案治疗晚期食管癌患者的效果。方法:选取2020年2月至2022年1月该院收治的62例晚期食管癌患者进行前瞻性研究,按随机数字表法将其分为对照组(n=31)和研究组(n=31)。对照组采用TP化疗方案治疗,研究组在对照组基础上联合盐酸安罗替尼治疗。比较两组临床疗效,治疗前后肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+))水平,以及不良反应发生率。结果:研究组疾病缓解率为77.42%(24/31),高于对照组的48.39%(15/31),差异有统计学意义(P<0.05);治疗后,两组CA125、CEA、VEGF水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均低于治疗前,但研究组高于对照组,两组CD8^(+)水平均高于治疗前,但研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:盐酸安罗替尼联合TP化疗方案治疗晚期食管癌患者可提高疾病缓解率,改善T细胞亚群指标水平,降低肿瘤标志物水平,其效果优于单纯TP化疗方案治疗。

Objective:To observe effects of Anlotinib hydrochloride combined with TP chemotherapy in treatment of patients with advanced esophageal cancer.Methods:A prospective study was conducted on 62 patients with advanced esophageal cancer admitted to the hospital from February 2020 to January 2022.They were divided into control group (n=31) and study group (n=31) by using the random number table method.The control group was treated with TP chemotherapy regimen,while the study group was treated with Anlotinib hydrochloride on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[carbohydrate antigen 125 (CA125),carcinoembryonic antigen (CEA),vascular endothelial growth factor (VEGF)]and T cell subsets (CD3^(+),CD4^(+),CD8^(+)) before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate of the study group was 77.42%(24/31),which was higher than 48.39%(15/31) of the control group,and the difference was statistically significant (P<0.05).After the treatment,the levels of CA125,CEA and VEGF in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05).After the treatment,the levels of CD3^(+)and CD4^(+)in the two groups were lower than those before the treatment,but those in the study group were higher than those in the control group;the levels of CD8^(+)in the two groups were higher than those before the treatment,but that in the study group was lower than that in the control group;and the differences were statistically significant (P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusions:Anlotinib hydrochloride combined with TP chemotherapy in the treatment of the patients with advanced esophageal cancer can improve the remission rate of the disease,improve the levels of T cell subsets,and reduce the levels of tumor markers.Moreover,it is superior to single TP chemotherapy.